

Prior Authorization Guideline

Guideline Name Short Acting Opioids Quantity Limit

Formulary OptumRx

Formulary Note

Approval Date 7/3/2017

Revision Date 7/3/2017

Technician Note :

P&T Approval Date: 3/22/2017 **Effective Date: 7/1/2017**

1 . Criteria

Product Name: Short Acting Opioids

Diagnosis	Cancer or end of life care
Approval Length	12 Month
Guideline Type	Quantity Limit
Approval Criteria	
1 Diagnosis of cancer or end of life care	
Notes	Note: Patients with a cancer drug in their prescription claims history within the previous 365 days will not be subject to a max daily dose, day supply, or fill restriction. Additionally, if criteria is approved patients will not be subject to a max daily dose, day supply, or fill restriction.

Product Name: Short Acting Opioids

Diagnosis	All Other Diagnoses
Approval Length	6 Month
Guideline Type	Quantity Limit

Approval Criteria

1 Prescriber certifies that there is an active treatment plan that includes but is not limited to a specific treatment objective and the use of other pharmacological and non-pharmacological agents for pain relief as appropriate

AND

2 Prescriber certifies that there has been an informed consent document signed and an addiction risk assessment has been performed

AND

3 Prescriber certifies that a written/signed agreement between prescriber and patient addressing issues of prescription management, diversion, and the use of other substances exists

Notes

Note: Patients with a cancer drug in their prescription claims history within the previous 365 days will not be subject to a max daily dose, day supply, or fill restriction. Additionally, if criteria is approved patients will not be subject to a max daily dose, day supply, or fill restriction.

2 . Background

Benefit/Coverage/Program Information

Short-acting opioids will be covered without prior authorization up to the following quantity limits:

New to therapy

Patients that are new to therapy (defined as having no opioids in their prescription claims history within the previous 120 days) will be subject to a quantity limit of 49 morphine milligram equivalents (MME) per day for up to two, 7-day supplies within a 60-day period.

Treatment experienced

Patients that are experienced on opioid therapy (defined as having prescriptions for opioids in their prescription claims history within the previous 120 days) will be subject to a quantity limit of 90 MME per day for up to two prescriptions within a 60-day period.

Note: Patients with a cancer drug in their prescription claims history within the previous 365 days will not be subject to a max daily dose, day supply, or fill restriction. Additionally, if criteria is approved patients will not be subject to a max daily dose, day supply, or fill restriction.

3 . References

1. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. DOI: <http://dx.doi.org/10.15585/mmwr.rr6501e1>